Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10473281 | 0.84 | — | — | |
| SCHEMBL25001139 | 0.81 | CNR1 (0.31) | — | |
| SCHEMBL10473359 | 0.77 | — | — | |
| SCHEMBL3157358 | 0.77 | — | — | |
| SCHEMBL13066536 | 0.77 | KDM4E (0.38) | MEN1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL13693058 | 0.77 | ADORA2A (0.39) | MEN1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL17542481 | 0.76 | MAPT (0.39) | MEN1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL8918080 | 0.75 | MEN1 (0.34) | MEN1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL10472357 | 0.75 | — | — | |
| SCHEMBL14044199 | 0.75 | GABRB3 (0.34) | MEN1CYP1A2CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155344-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-07 | — | — | US | disclosed |
| EP-3292127-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd (CH) | 2018-03-14 | — | — | EP | disclosed |
| EP-3071578-B1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-01-10 | — | — | EP | disclosed |
| US-9765092-B2 | Tricyclic piperidine compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-19 | — | — | US | disclosed |
| WO-2016177690-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-11-10 | — | — | WO | disclosed |
| EP-3071578-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd (CH) | 2016-09-28 | — | — | EP | disclosed |
| US-20160272655-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-09-22 | — | — | US | disclosed |
| WO-2015075023-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-05-28 | — | — | WO | disclosed |
| EP-1720545-B1 | BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES | CHEMOCENTRYX INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8138340-B2 | Bicyclononene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-20 | — | — | US | disclosed |
| EP-0453065-A1 | Triazolopyridine derivatives | ZENECA LIMITED (GB) | 1991-10-23 | — | — | EP | disclosed |
| EP-0442654-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1991-08-21 | — | — | EP | disclosed |
| EP-0442655-A2 | Benzisoxazole derivatives | ZENECA LIMITED (GB) | 1991-08-21 | — | — | EP | disclosed |
| US-4964895-A | Substituted 4-(4-nitrophenoxy) pyrazoles and their use as herbicides | MONSANTO COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| EP-0371947-A1 | Substituted pyrazoles and their use as herbicides | Monsanto Company (US) | 1990-06-06 | — | — | EP | disclosed |
| US-4855442-A | Substituted 3-hydroxy pyrazoles | MONSANTO COMPANY (US) | 1989-08-08 | — | — | US | disclosed |
| CN-1033457-A | 3-(4-nitrophenoxy) pyrazoles that replaces and as the purposes of weedicide | MONSANTO CO (US) | 1989-06-21 | — | — | CN | disclosed |
| CN-1031375-A | The oxazolidine dihaloacetamides class of 5-heterocyclic substituted | MONSANTO CO (US) | 1989-03-01 | — | — | CN | disclosed |
| EP-0304409-A1 | 5-Heterocyclic-substituted oxazolidine haloacetamides | MONSANTO COMPANY (US) | 1989-02-22 | — | — | EP | disclosed |
| EP-0295233-A2 | Substituted 3-(4-nitrophenoxy)pyrazoles and their use as herbicides | Monsanto Company (US) | 1988-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155344-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | TPH1, TPH2, HTR1B | MEN1 1152/4885CYP1A2 30/4885CYP2C9 70/4885 |
| US-20160272655-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | TPH1, HTR1B, HTR1A | MEN1 1689/4885CYP1A2 23/4885CYP2C9 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.